Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New MRI technique could reveal how well lung treatments are working

NCT ID NCT06012500

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing a special MRI technique using inhaled xenon gas to better see changes in the lungs of people with interstitial lung disease. Researchers want to make the method consistent across different hospitals and MRI machines. The goal is to help doctors quickly tell if a treatment is working, without invasive procedures.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Xenon-129 (inhaled contrast for MRI)
What this could lead to
If successful, this could make 129Xe MRI a reliable tool to see how well lung treatments are working, helping doctors personalize care for interstitial lung disease.
What could go wrong
This is an early-phase study focused on imaging methods, not a treatment. It may not lead to direct patient benefits, and results may vary across different MRI machines.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

78 people

The number who actually took part.

Started

Apr 2022

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 90 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Outpatients age 18 - 90 years old. 2. Subject has no diagnosed pulmonary conditions 3. Subject has not smoked in the previous 5 years 4. Smoking history, if any, is less than or equal to 5 pack-years Additional inclusion criteria for menstruation sub-study in healthy volunteers 1. Subject has a regular 26-30-day menstrual cycle 2. Subject is taking prescribed hormonal contraceptives that preserve a regular menstrual cycle. Exclusion Criteria: 1. MRI is contraindicated based on responses to MRI screening questionnaire 2. Subject is pregnant or lactating 3. Resting oxygen saturation on room air \<90% 4. Respiratory illness of a bacterial or viral etiology within 30 days of MRI 5. Subject has history of any known severe ventricular cardiac arrhythmia, as determined by the study physician. 6. Subject has history of cardiac arrest within the last year 7. Subject cannot hold their breath for 16 seconds

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ILD are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Cincinnati Children's Hospital Medical Center

    Cincinnati, Ohio, 45229, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.